131 results
1H, 13C and 15N chemical shift assignments of the C-terminal domain of human UDP-Glucuronosyltransferase 2B7 (UGT2B7-C).
Osborne MJ, Rahardjo AK, Volpon L, Borden K
Biomol NMR Assign
2021-04-18
;.
The Nuclear Pore Complex and mRNA Export in Cancer.
Borden K
Cancers (Basel)
2020-12-25
;13(
1
):.
The eukaryotic translation initiation factor eIF4E elevates steady-state m7G capping of coding and noncoding transcripts.
Culjkovic-Kraljacic B, Skrabanek L, Revuelta MV, Gasiorek J, Cowling VH, Cerchietti L, Borden K
Proc Natl Acad Sci U S A
2020-10-27
;117(
43
):26773-26783.
The diversity, plasticity, and adaptability of cap-dependent translation initiation and the associated machinery.
Borden K, Volpon L
RNA Biol
2020-06-04
;1-13.
Structural studies of the eIF4E-VPg complex reveal a direct competition for capped RNA: Implications for translation.
Coutinho de Oliveira L, Volpon L, Rahardjo AK, Osborne MJ, Culjkovic-Kraljacic B, Trahan C, Oeffinger M, Kwok B, Borden K
Proc. Natl. Acad. Sci. U.S.A.
2019-12-07
;116(
48
):24056-24065.
Nuclear eIF4E Stimulates 3’-End Cleavage of Target RNAs.
Davis MR, Delaleau M, Borden K
Cell Rep
2019-04-30
;27(
5
):1397-1408.e4.
Chemical shift assignment of the viral protein genome-linked (VPg) from potato virus Y.
Coutinho de Oliveira L, Volpon L, Osborne MJ, Borden K
Biomol NMR Assign
2019-04-01
;13(
1
):9-13.
GLI1-Inducible Glucuronidation Targets a Broad Spectrum of Drugs.
Zahreddine HA, Culjkovic-Kraljacic B, Gasiorek J, Duchaine J, Borden K
ACS Chem. Biol.
2019-03-15
;14(
3
):348-355.
CDK9 and mTOR: trading places.
Borden K
Blood
2019-03-14
;133(
11
):1167-1168.
Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia.
Urtishak KA, Wang LS, Culjkovic-Kraljacic B, Davenport JW, Porazzi P, Vincent TL, Teachey DT, Tasian SK, Moore JS, Seif AE, Jin S, Barrett JS, Robinson BW, Chen IL, Harvey RC, Carroll MP, Carroll AJ, Heerema NA, Devidas M, Dreyer ZE, Hilden JM, Hunger SP, Willman CL, Borden K, Felix CA
Oncogene
2019-03-01
;38(
13
):2241-2262.
Overcoming Drug Resistance through the Development of Selective Inhibitors of UDP-Glucuronosyltransferase Enzymes.
Osborne MJ, Coutinho de Oliveira L, Volpon L, Zahreddine HA, Borden K
J. Mol. Biol.
2019-01-18
;431(
2
):258-272.
Biochemical and Structural Insights into the Eukaryotic Translation Initiation Factor eIF4E.
Volpon L, Osborne MJ, Borden K
Curr. Protein Pept. Sci.
2019-01-01
;20(
6
):525-535.
The Impact of Post-transcriptional Control: Better Living Through RNA Regulons.
Culjkovic-Kraljacic B, Borden K
Front Genet
2018-11-05
;9:512.
Backbone assignment of the apo-form of the human C-terminal domain of UDP-glucuronosyltransferase 1A (UGT1A).
Osborne MJ, Coutinho de Oliveira L, Volpon L, Borden K
Biomol NMR Assign
2018-10-01
;12(
2
):315-318.
BRAF/MAPK and GSK3 signaling converges to control MITF nuclear export.
Ngeow KC, Friedrichsen HJ, Li L, Zeng Z, Andrews S, Volpon L, Brunsdon H, Berridge G, Picaud S, Fischer R, Lisle R, Knapp S, Filippakopoulos P, Knowles H, Steingrímsson E, Borden K, Patton EE, Goding CR
Proc. Natl. Acad. Sci. U.S.A.
2018-09-11
;115(
37
):E8668-E8677.
A TFEB nuclear export signal integrates amino acid supply and glucose availability.
Li L, Friedrichsen HJ, Andrews S, Picaud S, Volpon L, Ngeow K, Berridge G, Fischer R, Borden K, Filippakopoulos P, Goding CR
Nat Commun
2018-07-11
;9(
1
):2685.
The eukaryotic translation initiation factor eIF4E harnesses hyaluronan production to drive its malignant activity.
Zahreddine HA, Culjkovic-Kraljacic B, Emond A, Pettersson F, Midura R, Lauer M, Del Rincon S, Cali V, Assouline S, Miller WH, Hascall V, Borden K
Elife
2017-11-07
;6:.
A biochemical framework for eIF4E-dependent mRNA export and nuclear recycling of the export machinery.
Volpon L, Culjkovic-Kraljacic B, Sohn HS, Blanchet-Cohen A, Osborne MJ, Borden K
RNA
2017-06-01
;23(
6
):927-937.
The eukaryotic translation initiation factor eIF4E wears a “cap” for many occasions.
Borden K
Translation (Austin)
2016-08-10
;4(
2
):e1220899.
Importin 8 mediates m7G cap-sensitive nuclear import of the eukaryotic translation initiation factor eIF4E.
Volpon L, Culjkovic-Kraljacic B, Osborne MJ, Ramteke A, Sun Q, Niesman A, Chook YM, Borden K
Proc. Natl. Acad. Sci. U.S.A.
2016-05-10
;113(
19
):5263-8.
Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.
Culjkovic-Kraljacic B, Fernando TM, Marullo R, Calvo-Vidal N, Verma A, Yang S, Tabbò F, Gaudiano M, Zahreddine H, Goldstein RL, Patel J, Taldone T, Chiosis G, Ladetto M, Ghione P, Machiorlatti R, Elemento O, Inghirami G, Melnick A, Borden K, Cerchietti L
Blood
2016-02-18
;127(
7
):858-68.
Multiple Export Mechanisms for mRNAs.
Delaleau M, Borden K
Cells
2015-08-28
;4(
3
):452-73.
Molecular Pathways: GLI1-Induced Drug Glucuronidation in Resistant Cancer Cells.
Zahreddine HA, Borden K
Clin. Cancer Res.
2015-05-15
;21(
10
):2207-10.
Sonic Hedgehog factor Gli1: As good as resistant.
Zahreddine HA, Culjkovic-Kraljacic B, Borden K
Mol Cell Oncol
2015-02-24
;2(
1
):e961827.
A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E.
Assouline S, Culjkovic-Kraljacic B, Bergeron J, Caplan S, Cocolakis E, Lambert C, Lau CJ, Zahreddine HA, Miller WH, Borden K
Haematologica
2015-01-01
;100(
1
):e7-9.
The eukaryotic translation initiation factor eIF4E in the nucleus: taking the road less traveled.
Osborne MJ, Borden K
Immunol. Rev.
2015-01-01
;263(
1
):210-23.
When Will Resistance Be Futile?
Borden K
Cancer Res.
2014-12-15
;74(
24
):7175-7180.
MNKs act as a regulatory switch for eIF4E1 and eIF4E3 driven mRNA translation in DLBCL.
Landon AL, Muniandy PA, Shetty AC, Lehrmann E, Volpon L, Houng S, Zhang Y, Dai B, Peroutka R, Mazan-Mamczarz K, Steinhardt J, Mahurkar A, Becker KG, Borden K, Gartenhaus RB
Nat Commun
2014-11-18
;5:5413.
Inducible drug modification: A new form of resistance.
Culjkovic-Kraljacic B, Zahreddine HA, Borden K
Cell Cycle
2014-08-15
;13(
16
):2485-6.
TIF-90 tips the balance in rRNA synthesis.
Borden K
Blood
2014-07-24
;124(
4
):467-8.
The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation.
Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, Cormack G, Jaquith JB, Cerchietti L, Cocolakis E, Amri A, Bergeron J, Leber B, Becker MW, Pei S, Jordan CT, Miller WH, Borden K
Nature
2014-07-03
;511(
7507
):90-3.
LIMD2 Is a Small LIM-Only Protein Overexpressed in Metastatic Lesions That Regulates Cell Motility and Tumor Progression by Directly Binding to and Activating the Integrin-Linked Kinase.
Peng H, Talebzadeh-Farrooji M, Osborne MJ, Prokop JW, McDonald PC, Karar J, Hou Z, He M, Kebebew E, Orntoft T, Herlyn M, Caton AJ, Fredericks W, Malkowicz B, Paterno CS, Carolin AS, Speicher DW, Skordalakes E, Huang Q, Dedhar S, Borden K, Rauscher FJ
Cancer Res.
2014-03-01
;74(
5
):1390-403.
The eukaryotic translation initiation factor eIF4E is a direct transcriptional target of NF-κB and is aberrantly regulated in acute myeloid leukemia.
Hariri F, Arguello M, Volpon L, Culjkovic-Kraljacic B, Nielsen TH, Hiscott J, Mann KK, Borden K
Leukemia
2013-10-01
;27(
10
):2047-55.
Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma.
Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW, Wyman S, Leser M, Shaknovich R, Chadburn A, Tabbo F, Godley LA, Gascoyne RD, Borden K, Inghirami G, Leonard JP, Melnick A, Cerchietti L
Cancer Discov
2013-09-01
;3(
9
):1002-1019.
Aiding and abetting cancer: mRNA export and the nuclear pore.
Culjkovic-Kraljacic B, Borden K
Trends Cell Biol.
2013-07-01
;23(
7
):328-35.
RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth.
Romeo Y, Moreau J, Zindy PJ, Saba-El-Leil M, Lavoie G, Dandachi F, Baptissart M, Borden K, Meloche S, Roux PP
Oncogene
2013-06-13
;32(
24
):2917-26.
Conformational changes induced in the eukaryotic translation initiation factor eIF4E by a clinically relevant inhibitor, ribavirin triphosphate.
Volpon L, Osborne MJ, Zahreddine H, Romeo AA, Borden K
Biochem. Biophys. Res. Commun.
2013-05-10
;434(
3
):614-9.
The Oncogene eIF4E: Using Biochemical Insights to Target Cancer.
Carroll M, Borden K
J. Interferon Cytokine Res.
2013-05-01
;33(
5
):227-38.
eIF4E3, a new actor in mRNA metabolism and tumor suppression.
Volpon L, Osborne MJ, Culjkovic-Kraljacic B, Borden K
Cell Cycle
2013-04-15
;12(
8
):1159-60.
eIF4E3 acts as a tumor suppressor by utilizing an atypical mode of methyl-7-guanosine cap recognition.
Osborne MJ, Volpon L, Kornblatt JA, Culjkovic-Kraljacic B, Baguet A, Borden K
Proc. Natl. Acad. Sci. U.S.A.
2013-03-05
;110(
10
):3877-82.
Mechanisms and insights into drug resistance in cancer.
Zahreddine H, Borden K
Front Pharmacol
2013-01-01
;4:28.
MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In Vivo.
Fontan L, Yang C, Kabaleeswaran V, Volpon L, Osborne MJ, Beltran E, Garcia M, Cerchietti L, Shaknovich R, Yang SN, Fang F, Gascoyne RD, Martinez-Climent JA, Glickman JF, Borden K, Wu H, Melnick A
Cancer Cell
2012-12-11
;22(
6
):812-24.
The oncogene eIF4E reprograms the nuclear pore complex to promote mRNA export and oncogenic transformation.
Culjkovic-Kraljacic B, Baguet A, Volpon L, Amri A, Borden K
Cell Rep
2012-08-30
;2(
2
):207-15.
Structural insights into the allosteric effects of 4EBP1 on the eukaryotic translation initiation factor eIF4E.
Siddiqui N, Tempel W, Nedyalkova L, Volpon L, Wernimont AK, Osborne MJ, Park HW, Borden K
J. Mol. Biol.
2012-02-03
;415(
5
):781-92.
The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML).
Assouline S, Cocolakis E, Borden K
Cancers (Basel)
2012-01-01
;4(
4
):1161-79.
mRNA export and cancer.
Siddiqui N, Borden K
Wiley Interdiscip Rev RNA
2012-01-01
;3(
1
):13-25.
Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens.
Kraljacic BC, Arguello M, Amri A, Cormack G, Borden K
Leukemia
2011-07-01
;25(
7
):1197-200.
Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer.
Pettersson F, Yau C, Dobocan MC, Culjkovic-Kraljacic B, Retrouvay H, Puckett R, Flores LM, Krop IE, Rousseau C, Cocolakis E, Borden K, Benz CC, Miller WH
Clin. Cancer Res.
2011-05-01
;17(
9
):2874-84.
Activation loop phosphorylation of ERK3/ERK4 by group I p21-activated kinases (PAKs) defines a novel PAK-ERK3/4-MAPK-activated protein kinase 5 signaling pathway.
Déléris P, Trost M, Topisirovic I, Tanguay PL, Borden K, Thibault P, Meloche S
J. Biol. Chem.
2011-02-25
;286(
8
):6470-8.
Targeting the oncogene eIF4E in cancer: From the bench to clinical trials.
Borden K
Clin Invest Med
2011-01-01
;34(
6
):E315.